Ascension Medical Biotechnology, a company focused on exosome function induction technology, recently announced that it signed a "Pharmaceutical Project Co-Development Agreement" with the Medical & Pharmaceutical Industry Tech & Dev Center on August 30. This partnership marks the official launch of several biotech and pharmaceutical development projects, enabling the company to enter the billion-dollar pharmaceutical market.
Ascension Medical Biotechnology stated that the company, leveraging its proprietary Biochemical Pulse international invention patent technology, has applied this innovation to various medical and cosmetic hair growth studies. Their first commercialized product, ExoGiov, is the world's first exosome specifically designed for skin beauty and hair growth. Unlike other non-functionally induced exosomes (Naive Exosome), ExoGiov received the international cosmetics INCI certification in 2022. Its exceptional efficacy, market uniqueness, and ease of use—enabling exosome freeze-dried powders, solutions, and skincare products to be stored and used at room temperature—have driven exponential revenue growth.
For a biotech startup that is only three years old, Ascension Medical Biotechnology’s revenue performance has been impressive. Now, by entering the pharmaceutical market with even greater potential and collaborating with the experienced Medical & Pharmaceutical Industry Tech & Dev Center on drug development projects, the company is optimistic about the future outcomes of these initiatives. This collaboration could significantly enhance the company's value, positioning it as a leading biotech enterprise in Taiwan.
Chairman Ju-Sheng Shieh of Ascension Medical Biotechnology noted that the company’s Biochemical Pulse invention patent technology, besides its applications in cosmetic hair growth, has also shown promising results in obstetrics and gynecology, dentistry, ophthalmology, nephrology, orthopedics, otology, and major wound repair. Preclinical efficacy tests have been completed, and most have undergone animal testing, demonstrating competitive therapeutic potential to address unmet medical needs in these fields. The company has already filed related international invention patents and plans to publish four international papers shortly. Whether in cosmetics or pharmaceuticals, the company has always adhered to the principle of developing and marketing products that are compliant with legal and regulatory standards. The company is now officially initiating the application development of pharmaceutical projects in accordance with relevant international pharmaceutical regulations.
The Medical & Pharmaceutical Industry Tech & Dev Center is the leading pharmaceutical professional team in Taiwan, with expertise in drug project development planning and familiarity with international pharmaceutical regulations. After multiple discussions and planning sessions between both teams, they have decided to officially launch several drug development projects for Ascension Medical Biotechnology in September this year. This agreement also signifies a new milestone in Ascension Medical Biotechnology’s development, marking its formal entry into the field of biotech pharmaceutical development.
Resource (mandarin): 陞醫生技攜手藥技中心啟動多項醫藥開發 進軍醫藥市場
